literature

HBV mutation literature information.

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.

PMID: 10377169 1999 The Journal of clinical investigation

Abstract: In this study, susceptibility of wild-type and lamivudine-resistant HBV M552I, M552V, and L528M/M552V mutants to other reverse transcriptase inhibitors was investigated by transient transfection of full-length HBV DNA into human hepatoma cells.

Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine.

PMID: 9551691 1998 Journal of hepatology

Abstract: RESULTS: Sequencing studies of HBV DNA at week 52 showed the emergence of a lamivudine-resistant variant associated with two point mutations in the hepatitis B virus polymerase gene: one mutation led to amino acid substitution of methionine to valine at residue 552, in the highly conserved tyrosine-methionineaspartate-aspartate motif, part of the active site of the polymerase; the second mutation consisted of a substitution of leucine to methionine at residue 528.

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

PMID: 9620341 1998 Hepatology (Baltimore, Md.)

Abstract: HBV DNA from the sera of patients in Group I exhibits a substitution of valine for methionine at residue 552, accompanied by a substitution of methionine for leucine at residue 528.

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.

PMID: 9828233 1998 Hepatology (Baltimore, Md.)

Abstract: HBV DNA polymerase mutants M552I, M552V, and L528M/M552V showed resistance to lamivudine triphosphate with inhibition constants (Ki) increased by 8.0-fold, 19.6-fold, and 25.2-fold compared with that of wild-type HBV DNA polymerase.

Browser Board

Co-occurred Entities

Filtrator